Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Abnormal lymph vessels show heightened growth signaling regardless of key gene mutation (opens in a new tab)

medicalxpress.com · 2026-10-06

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 5 supported
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Five of eight claims match the study. This overall rating is based only on the claims we could check. Three claims the study doesn't address.

  • 5 supported
  • 3 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

8 claims in this story

Showing all 8 claimsChoose a verdict to focus the list.

Claim 1 of 8Not coveredLymphatic malformations are rare disorders in which lymph vessels develop abnormally, often starting in childhood and sometimes causing swelling, infection, bleeding, pain or airway obstruction.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that lymphatic malformations are rare vascular malformations, but it does not provide evidence for the stated childhood onset pattern or the listed symptoms such as swelling, infection, bleeding, pain, or airway obstruction. Those background details may be true, but they are not verifiable from the supplied abstract-depth paper profile.

1

Study evidence

Somatic PIK3CA mutations were detected in 20 of 34 LMs.58.8%

“We retrospectively analyzed 34 LM cases.”
Claim 2 of 8Not coveredThese findings are described as consistent with the clinical effectiveness of sirolimus, a drug that targets this pathway, across patients with lymphatic malformations.View evidenceHide evidence

Why this verdict

The profile supports pathway activation regardless of PIK3CA status, but it does not mention sirolimus or clinical effectiveness of sirolimus across LM patients. That interpretation may appear outside the abstract, but it is not verifiable from the supplied abstract-depth profile.

1

Study evidence

PI3K/AKT/mTOR pathway activation in LECs is higher in lymphatic malformations than in normal lymphatic vessels.

“We also evaluated clinical and histopathological findings and performed immunohistochemistry.”
Claim 3 of 8Not coveredThe findings suggest that the calcineurin-NFAT pathway may also contribute to disease pathogenesis and could represent a future therapeutic target.View evidenceHide evidence

Why this verdict

The profile supports the cautious inference that calcineurin–NFAT signaling may be involved in LM pathogenesis based on NFATC1 expression. However, the supplied abstract-depth profile does not verify the additional claim that the pathway could be a future therapeutic target; it also notes that the expression evidence is correlative and not functional proof.

1

Study evidence

Spatial transcriptomics on two PIK3CA-mutant LM cases found 10 genes upregulated in LEC-containing regions; NFATC1 was highly expressed in LM LECs, leading to the suggestion that calcineurin–NFAT signaling may play a role in LM pathogenesis.10 genes upregulated in LEC-containing regions (NFATC1 among them)

“Spatial transcriptomics was performed on two PIK3CA-mutant LM cases.”
Claim 4 of 8SupportedResearchers led by the University of Osaka combined genetic analysis with detailed examination of patient tissues to uncover common features of the disease and identify molecular clues that could inform future treatment strategies.View evidenceHide evidence

Why this verdict

The paper profile supports that the study combined PIK3CA genetic testing, clinicopathological/histopathological tissue assessment, immunohistochemistry, and spatial transcriptomics to identify shared disease features and molecular clues. The treatment-strategy language is hedged and broadly consistent with the molecular-pathway focus, although the University of Osaka affiliation itself is not independently evidenced in the supplied scientific profile.

1

Study evidence

Somatic PIK3CA mutations were detected in 20 of 34 LMs.58.8%

“We retrospectively analyzed 34 LM cases.”
2

Study evidence

PI3K/AKT/mTOR pathway activation in LECs is higher in lymphatic malformations than in normal lymphatic vessels.

“We also evaluated clinical and histopathological findings and performed immunohistochemistry.”
Claim 5 of 8SupportedIn tissue samples from 34 patients, PIK3CA changes were detected in 20 patients, or 58.8%.View evidenceHide evidence

As stated20 of 34 patients (58.8%)

Why this verdict

The abstract explicitly reports somatic PIK3CA mutations in 20 of 34 cases, corresponding to 58.8%.

1

Study evidence

Somatic PIK3CA mutations were detected in 20 of 34 LMs.58.8%

“We retrospectively analyzed 34 LM cases.”
Claim 6 of 8SupportedMost clinical features were similar whether or not a PIK3CA mutation was detected, but malformed vessels showed a more scattered growth pattern in patients carrying PIK3CA mutations.View evidenceHide evidence

Why this verdict

The profile states that clinical variables and most histopathological parameters were comparable between PIK3CA-mutant and non-mutant LMs, while mutant LMs more often showed a scattered growth pattern of malformed vessels.

1

Study evidence

Somatic PIK3CA mutations were detected in 20 of 34 LMs.58.8%

“We retrospectively analyzed 34 LM cases.”
Claim 7 of 8SupportedThe PI3K/AKT/mTOR pathway was more active in malformed lymphatic vessels than in normal vessels regardless of PIK3CA mutation status, and AKT activity increased with patient age.View evidenceHide evidence

Why this verdict

The abstract-level profile states that immunohistochemistry showed higher PI3K/AKT/mTOR pathway activation in LM lymphatic endothelial cells than in normal lymphatic vessels, independent of PIK3CA status, and that phosphorylated AKT levels significantly increased with age.

1

Study evidence

PI3K/AKT/mTOR pathway activation in LECs is higher in lymphatic malformations than in normal lymphatic vessels.

“We also evaluated clinical and histopathological findings and performed immunohistochemistry.”
Claim 8 of 8SupportedSpatial transcriptomic analysis in two PIK3CA-mutant cases found ten genes that were more active in malformed lymphatic vessels in both cases, including strong NFATC1 expression in endothelial cells lining the malformed vessels.View evidenceHide evidence

As statedtwo PIK3CA-mutant cases; ten genes

Why this verdict

The profile reports spatial transcriptomics in two PIK3CA-mutant LM cases, identification of 10 upregulated genes in LEC-containing regions, and high NFATC1 expression in LM lymphatic endothelial cells.

1

Study evidence

Spatial transcriptomics on two PIK3CA-mutant LM cases found 10 genes upregulated in LEC-containing regions; NFATC1 was highly expressed in LM LECs, leading to the suggestion that calcineurin–NFAT signaling may play a role in LM pathogenesis.10 genes upregulated in LEC-containing regions (NFATC1 among them)

“Spatial transcriptomics was performed on two PIK3CA-mutant LM cases.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Malformed-vessel microenvironmental features such as fibrous stroma, lymphoid aggregates, and macrophages were commonly present regardless of PIK3CA status.

    This is listed as an abstract-level finding in the paper profile, but the story does not specifically report these microenvironmental features.

    From Retrospective case series

8 things the story did carry across
  • Retrospective case-series design with 34 lymphatic malformation cases and PIK3CA testing by targeted next-generation sequencing.
  • Somatic PIK3CA mutations were detected in 20/34 cases, or 58.8%.
  • Clinical variables and most histopathological parameters were comparable by PIK3CA status, but mutant LMs more often had a scattered malformed-vessel growth pattern.
  • Immunohistochemistry showed increased PI3K/AKT/mTOR pathway activation in LM lymphatic endothelial cells compared with normal lymphatic vessels, independent of PIK3CA status.
  • Phosphorylated AKT levels increased significantly with patient age.
  • Spatial transcriptomics was performed on only two PIK3CA-mutant LM cases and identified 10 upregulated genes in LEC-containing regions, including high NFATC1 expression.
  • The calcineurin–NFAT pathway implication is inferential from expression data and is not functional or causal proof.
  • The spatial transcriptomics findings are restricted to PIK3CA-mutant cases and may not generalize to non-mutant lymphatic malformations.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataRelate somatic PIK3CA mutation status in lymphatic malformations (LMs) to clinical presentation and histopathological features in a retrospective case series.Retrospective case seriesExpand

In plain English

Retrospective case-series of 34 lymphatic malformations (LMs) in which somatic PIK3CA mutation status was determined by targeted next-generation sequencing (custom gene panel) and compared with clinical variables and histopathological features to assess genotype–phenotype associations.

Key findings

  • Somatic PIK3CA mutations were detected in 20 of 34 LMs.58.8%
  • Clinical variables (age, sex, lesion location) and most histopathological parameters were comparable between PIK3CA-mutant and non-mutant LMs.
“We retrospectively analyzed 34 LM cases.”
What this piece can’t prove
  • Retrospective case-series design.
  • Modest cohort size (34 cases), limiting statistical power.
  • Possible selection and referral biases inherent to retrospective single-cohort studies; sampling/frame not detailed in abstract.

1 further detail could not be confirmed from the summary.

2ex vivo humanCharacterize LM microenvironment and PI3K/AKT/mTOR pathway activation in lymphatic endothelial cells (LECs) and assess associations with PIK3CA status and age using immunohistochemistry.ex vivo human IHC on archived LM and normal lymphatic tissue (retrospective cohort)Expand

In plain English

Immunohistochemistry on a retrospective cohort of 34 lymphatic malformations (LMs) showed increased PI3K/AKT/mTOR pathway activation in lymphatic endothelial cells (LECs) of LMs compared with normal lymphatic vessels, independent of PIK3CA mutation status; phosphorylated AKT (p-AKT) levels in LMs increased with patient age.

Key findings

  • PI3K/AKT/mTOR pathway activation in LECs is higher in lymphatic malformations than in normal lymphatic vessels.
  • Elevated PI3K/AKT/mTOR activation in LM LECs was reported to be independent of PIK3CA mutation status.
“We also evaluated clinical and histopathological findings and performed immunohistochemistry.”
What this piece can’t prove
  • Relatively small retrospective cohort (34 cases) may limit generalizability and subgroup analyses by mutation status or age strata.

2 further details could not be confirmed from the summary.

3ex vivo humanUse spatial transcriptomics on PIK3CA-mutant LM tissue to identify LEC-region gene expression programs (including NFATC1) implicating calcineurin–NFAT signaling in LM pathogenesis.Spatial transcriptomics on two PIK3CA-mutant LM cases; region-based differential expression in LEC-containing areasExpand

In plain English

Spatial transcriptomics on two PIK3CA-mutant lymphatic malformation (LM) samples identified 10 genes upregulated in lymphatic endothelial cell (LEC)-containing regions; NFATC1 was among the highly expressed genes, leading authors to suggest involvement of the calcineurin–NFAT pathway in LM pathogenesis.

Key findings

  • Spatial transcriptomics on two PIK3CA-mutant LM cases found 10 genes upregulated in LEC-containing regions; NFATC1 was highly expressed in LM LECs, leading to the suggestion that calcineurin–NFAT signaling may play a role in LM pathogenesis.10 genes upregulated in LEC-containing regions (NFATC1 among them)
“Spatial transcriptomics was performed on two PIK3CA-mutant LM cases.”
What this piece can’t prove
  • Very small sample size (spatial transcriptomics performed on two cases).
  • Abstract provides limited methodological detail (e.g., selection/segmentation criteria for LEC regions, statistical thresholds, and whether results were validated).
  • Findings restricted to PIK3CA-mutant specimens; generalizability to other LMs unclear.
  • Expression-based pathway implication is correlative and not evidence of functional causation.
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 38 candidate papers

Candidate

1145 Acute Myeloid Leukemia with Aberrant PAX5 Expression: Comprehensive clinicopathologic and molecular correlation

Laboratory Investigation · 2026 · Crossref

Source (opens in a new tab)

And 32 more candidates considered.